Results 51 to 60 of about 24,516 (282)

Complement blockade for TA-TMA: lessons learned from large pediatric cohort treated with eculizumab.

Blood, 2020
Overactivated complement is a high-risk feature in HSCT recipients with transplant associated thrombotic microangiopathy (TA-TMA), and untreated patients have dismal outcomes.
S. Jodele, C. Dandoy, A. Lane, B. Laskin, Ashley Teusink‐Cross, K. Myers, G. Wallace, A. Nelson, J. Bleesing, Ranjit S Chima, R. Hirsch, T. Ryan, S. Benoit, Kana Mizuno, Mikako Warren, S. Davies   +15 more
semanticscholar   +1 more source

Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review

Pediatric nephrology (Berlin, West), 2023
Infection-associated hemolytic uremic syndrome (IA-HUS), most often due to infection with Shiga toxin-producing bacteria, mainly affects young children.
P. D. de Zwart, Thomas F Mueller, G. Spartà, V. Luyckx   +3 more
semanticscholar   +1 more source

Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment [PDF]

, 2017
Los datos asociados con este artículo están disponibles en: http://dx.doi.org/10.1016/j.imbio.2016.09.002.Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic anemia characterized by complement-mediated intravascular hemolysis that is ...
Anter, Jaouad, Ataúlfo Gonzalez-Fernández, Fernando, Forés, Rafael, García, Sheila Pinto, López, Alicia, López-Trascasa, Margarita, Martin Merinero, Hector, Ojeda, Emilio, Rodríguez de Córdoba, Santiago, Subías Hidalgo, Marta, Villegas, Ana   +10 more
core   +2 more sources

Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition

American journal of hematology/oncology
Crovalimab is a novel C5 complement inhibitor that enables rapid and sustained C5 inhibition with subcutaneous, low‐volume self‐administration every 4 weeks.
Alexander Röth, Guangsheng He, Hongyan Tong, Zenghua Lin, Xiaoqin Wang, C. Chai-Adisaksopha, Je-Hwan Lee, Andres Brodsky, Chattree Hantaweepant, Teresita E. Dumagay, Roberta Demichelis-Gómez, P. Rojnuckarin, Jing Sun, Martin Höglund, Jun-Ho Jang, A. Gaya, Fernando Silva, N. Obara, Richard J. Kelly, Leigh Beveridge, Simon Buatois, S. Chebon, Brittany Gentile, Pontus Lundberg, S. Sreckovic, Jun-Ichi Nishimura, A. Risitano, Bing Han   +27 more
semanticscholar   +1 more source

Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizimab treatment [PDF]

, 2016
Background: Eculizumab is approved for atypical hemolytic uremic syndrome (aHUS). Guidelines discuss the importance of prompt treatment. We report a post hoc analysis investigating the effect of baseline factors, including patient characteristics and ...
Ardissimo, Gianluigi, Delmas, Yahsou, Haller, Herman, Kincaid, John F, Vande Walle, Johan, Wang, Jimmy   +5 more
core   +2 more sources

Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study

Therapeutic Advances in Neurological Disorders, 2020
Background: In the phase III eculizumab for refractory generalized myasthenia gravis REGAIN study [ClinicalTrials.gov identifier: NCT01997229] and its open-label extension (OLE) [ClinicalTrials.gov identifier: NCT02301624], patients with treatment ...
Saiju Jacob, Hiroyuki Murai, Kimiaki Utsugisawa, Richard J. Nowak, Heinz Wiendl, Kenji P. Fujita, Fanny O’Brien, James F. Howard   +7 more
doaj   +1 more source

Long‐term effectiveness of eculizumab: Data from the International PNH Registry

European Journal of Haematology, 2023
Data from the International PNH Registry (NCT01374360) were used to estimate the overall survival and first occurrence of thromboembolic events/major adverse vascular events (TEs/MAVEs) for eculizumab‐treated patients with paroxysmal nocturnal ...
L. Terriou, Jong Wook Lee, Cecily Forsyth, Morag Griffin, J. Szer, Alexander Röth, Philippe Gustovic, Jesse Metzger, Ami S. Patel, Christopher J. Patriquin   +9 more
semanticscholar   +1 more source

Pharmacokinetics and Pharmacodynamics Estimation of Eculizumab in a 2-Year-Old Girl With Atypical Hemolytic Uremic Syndrome: A Case Report With 4-Year Follow-Up

Frontiers in Pediatrics, 2019
Background: Eculizumab has dramatically changed poor outcomes of complement-mediated atypical hemolytic uremic syndrome (aHUS) as first-line treatment. Discontinuation of eculizumab remains challenging, and doctor's visits every 2 weeks for intravenous ...
Ken Saida, Tsuyoshi Fukuda, Kana Mizuno, Masao Ogura, Koichi Kamei, Shuichi Ito   +5 more
doaj   +1 more source

Eculizumab for Gemcitabine-Induced Hemolytic Uremic Syndrome: A Novel Therapy for an Emerging Condition [PDF]

, 2015
Introduction Atypical hemolytic uremic syndrome (aHUS), a thrombotic microangiopathy (TMA), is a disease characterized by hemolytic anemia, thrombocytopenia, and renal impairment. Gemcitabine, a commonly used chemotherapy, is emerging as a cause of aHUS.
Karkowsky, MD, Raphael, Parikh, MD, Kinjal   +1 more
core   +2 more sources

Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH

Blood
Key Points • Danicopan + ravulizumab/eculizumab show long-term efficacy for continued control of terminal complement, intravascular hemolysis, and cs-EVH.• Danicopan demonstrated a favorable benefit-risk profile, with a breakthrough hemolysis rate of 6 ...
A. Kulasekararaj, Morag Griffin, C. Piatek, J. Shammo, Jun-Ichi Nishimura, Christopher J. Patriquin, H. Schrezenmeier, W. Barcellini, J. Panse, A. Gaya, Y. Patel, Peng Liu, Gleb Filippov, F. Sicre de Fontbrune, A. Risitano, Jong Wook Lee   +15 more
semanticscholar   +1 more source